Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
Zydus Research Center, Sarkhej-Bavla NH 8A, Moraiya, Ahmedabad, 382 210, Gujarat, India. nuggehally.srinivas@zyduscadila.com.
Nuggehally R
NR
Srinivas
D000069501:Abiraterone Acetate; D000736:Androstenes; D000971:Antineoplastic Combined Chemotherapy Protocols; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant; D043823:Taxoids; D016896:Treatment Outcome
D000736:Androstenes; D043823:Taxoids; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate; C089740:abiraterone